Finance

Beta
Lists
500087:BOM
Cipla Ltd
₹1,373.95
-0.36%
(-4.95) 1D
Jun 3, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500087...
Open
₹1,361.05
High
₹1,384.80
Low
₹1,361.05
Mkt. cap
1.11T
Avg. vol.
137.47K
Volume
15.21K
Dividend
0.95%
Quarterly dividend
₹3.25
Ex-dividend date
Jun 5, 2026
P/E ratio
28.61
52-wk high
₹1,672.20
52-wk low
₹1,165.55
EPS
₹48.03
Shares outstanding
805.67M
No. of employees
30K
Open
₹1,361.05
High
₹1,384.80
Low
₹1,361.05
Mkt. cap
1.11T
Avg. vol.
137.47K
Volume
15.21K
Dividend
0.95%
Quarterly dividend
₹3.25
Ex-dividend date
Jun 5, 2026
P/E ratio
28.61
52-wk high
₹1,672.20
52-wk low
₹1,165.55
EPS
₹48.03
Shares outstanding
805.67M
No. of employees
30K
News stories
From sources across the web
Profile
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
About Cipla Ltd
CEOUmang Vohra
Employees30.3K
Founded1935
HeadquartersMumbai, Maharashtra, India
SectorPharmaceutical industry
Websitecipla.com
Last report
May 13, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹6.86 / ₹9.67
-29.07%miss
Revenue / Est. (INR)
65.80B / 67.14B
-1.99%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
68.37B
74.47B
69.63B
65.80B
Cost of goods sold
21.71B
24.98B
26.32B
25.10B
Cost of revenue
21.71B
24.98B
26.32B
25.10B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.12B
13.15B
13.25B
28.23B
Operating expense
31.41B
33.52B
33.54B
33.30B
Total operating expenses
53.12B
58.50B
59.86B
58.39B
Operating income
15.25B
15.98B
9.77B
7.41B
Other non operating income
2.59B
2.69B
2.06B
-5.35B
EBT including unusual items
17.69B
18.54B
8.93B
6.99B
EBT excluding unusual items
17.69B
18.54B
11.69B
4.51B
Income tax expense
4.78B
5.00B
2.19B
1.57B
Effective tax rate
27.01%
27.00%
24.48%
22.44%
Other operating expenses
15.76B
17.40B
17.51B
2.51B
Net income
12.98B
13.51B
6.76B
5.55B
Net profit margin
18.98%
18.14%
9.71%
8.43%
Earnings per share
16.06
16.72
10.94
6.86
Interest and investment income
-
-
-
2.07B
Interest expense
-140.50M
-131.80M
-140.30M
-69.70M
Net interest expenses
-140.50M
-131.80M
-140.30M
2.00B
Depreciation and amortization charges
2.53B
2.97B
2.78B
2.56B
EBITDA
17.49B
18.73B
12.00B
9.82B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more